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Abstract
Background: Prediction scoring systems for coronary artery bypass grafting (CABG) patients on venoarterial
extracorporeal membrane oxygenation (VA-ECMO) have not yet been reported. This study was designed to develop
a predictive score for in-hospital mortality for cardiogenic shock patients who received VA-ECMO after isolated
CABG.
Methods: Retrospective cohort study of consecutive CABG patients supported with VA-ECMO (n = 166) at the
Beijing Anzhen Hospital between February 2004 and March 2017.
Results: One hundred and six patients (64%) could be weaned from VA-ECMO, and 74 patients (45%) survived
to hospital discharge. On the basis of multivariable logistic regression analyses, the pRedicting mortality in
patients undergoing veno-arterial Extracorporeal MEMBrane oxygenation after coronary artEry bypass gRafting
(REMEMBER) score was created with six pre-ECMO parameters: older age, left main coronary artery disease,
inotropic score > 75, CK-MB > 130 IU/L, serum creatinine > 150 umol/L, and platelet count < 100 × 109/L. Four
risk classes, namely class I (REMEMBER score 0–13), class II (14–19), class III (20–25), and class IV (> 25) with
their corresponding mortality (13%, 55%, 70%, and 94%, respectively), were identified. The area under the
receiver operating characteristic curve 0.85(95% CI 0.79–0.91) for the REMEMBER score was better than those
for the SOFA, SAVE, EuroSCORE, and ENCOURAGE scores in this population.
Conclusions: The REMEMBER score might help clinicians at bedside to predict in-hospital mortality for
patients receiving VA-ECMO after isolated CABG for refractory cardiogenic shock. Prospective studies are
needed to externally validate this scoring system.
Keywords: Cardiogenic shock, Venoarterial extracorporeal membrane oxygenation, Coronary artery bypass
grafting, pRedicting mortality in patients undergoing veno-arterial Extracorporeal MEMBrane oxygenation after
coronary artEry bypass gRafting (REMEMBER) score, Mortality
Background
Approximately 1% of patients who undergo coronary ar-
tery bypass grafting (CABG) experience refractory post-
cardiotomy cardiogenic shock (PCS), which is associated
with increased morbidity and mortality [1–3]. In these
patients, venoarterial extracorporeal membrane oxygen-
ation (VA-ECMO) may be considered as a rescue
strategy to provide temporary circulatory and respiratory
support allowing cardiac function recovery or bridging
to additional therapeutic alternatives [4–6]. Despite
major innovations in ECMO support over the last few
decades, in-hospital mortality from cardiogenic shock in
post-CABG patients supported with VA-ECMO remains
high [1–3, 5–13]. Early identification of pre-ECMO fac-
tors associated with mortality may prognosticate in
post-CABG patients. In this context, the survival after
VA-ECMO (SAVE) score for refractory cardiogenic
shock in general and the prEdictioN of Cardiogenic
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shock OUtcome foR Acute myocardial infarction pa-
tients salvaGed by VA-ECMO (ENCOURAGE) risk
score have been published over the past few years [14,
15]. However, there are currently few studies reporting
mortality risk factors and clinical outcomes of PCS
patients who were supported with VA-ECMO after
CABG [6, 7]. In addition, prediction scoring systems
for CABG patients on VA-ECMO have not yet been
reported. We developed the pRedicting mortality in
patients undergoing veno-arterial Extracorporeal
MEMBrane oxygenation after coronary artEry bypass
gRafting (REMEMBER) score, which might help the




We retrospectively evaluated consecutive patients who
received VA-ECMO between February 2004 and March
2017 at the Beijing Anzhen Hospital. Patients were en-
rolled in the study if they received VA-ECMO treatment
for refractory PCS after isolated CABG. The clinical cri-
teria for PCS [2, 16] included the following: left atrial
pressure > 15 mmHg; central venous pressure > 12
mmHg; metabolic acidosis (i.e., pH < 7.3 with serum lac-
tate > 3.0 mmol/L); end-organ hypoperfusion (urine out-
put < 30 mL/h); cardiac index < 2.2 L/min/m2; and
systolic blood pressure < 80mmHg despite adequate fill-
ing volumes, use of multiple adrenergic agents (epineph-
rine > 0.1 μg/kg/min or dobutamine > 10 μg/kg/min,
norepinephrine > 0.1 μg/kg/min), or an intra-aortic bal-
loon pump (IABP). Exclusion criteria for patient selec-
tion from our institutional ECMO database were an age
< 18 years, venovenous ECMO support for acute respira-
tory failure, ECMO initiation before CABG or at more
than 7 days after CABG, and concomitant other major
cardiac procedures (valvular replacement, valvuloplasty,
or aortic surgery). The study was approved by the insti-
tutional ethics committee/review board of the Beijing
Anzhen Hospital (2016005X), and the requirement for
informed patient consent was waived in view of the
retrospective nature of the study.
ECMO implantation and management
The details regarding VA-ECMO initiation and manage-
ment have been described previously [3]. Briefly,
VA-ECMO support was initiated via peripheral cannula-
tion through the femoral route with the semi-open
method, and an additional 6 Fr catheter was systematic-
ally inserted distally into the femoral artery to prevent
severe leg ischemia. All procedures were performed by
trained ECMO team members. ECMO blood flow was
adjusted based on clinical assessments (e.g., mixed ven-
ous oxygen saturation, evidence of hypoperfusion,
resolution of hyperlactatemia, normalization of mean ar-
terial pressure). Intravenous unfractionated heparin was
given to maintain an activated clotting time of 180–210
s, or an activated partial thromboplastin time of 1.5–2
times normal. ECMO-related complications were care-
fully monitored. When patients fulfilled our institutional
weaning criteria, a protocolized weaning trial was per-
formed [17, 18]. Weaning was considered unsuccessful if
ECMO re-cannulation was required within 2 days of
decannulation. (See supplementary material online for
weaning criteria and data collection.)
Outcomes and definitions
The primary outcome was in-hospital mortality, defined as
death from any cause occurring in patients who were
treated by VA-ECMO for PCS post CABG. Secondary out-
comes included ECMO duration, length of intensive care
unit (ICU) stay, length of hospital stay, survival to ECMO
weaning, continuous renal replacement therapy (CRRT),
systemic infection, bleeding requiring thoracotomy, major
neurological complications, and major ECMO-related com-
plications. Systemic infection was defined by a positive
blood culture. Major neurological complications included
brain death, ischemic stroke, hemorrhagic stroke, and an-
oxic encephalopathy. Major ECMO-related complications
included femoral hemorrhage due to arterial laceration, leg
ischemia requiring surgical intervention (fasciotomy or am-
putation), infection at the site of ECMO cannula insertion,
cannula thrombosis, and need for an oxygenator change.
Statistical analysis
All the analyses were performed with STATA /SE 12.0
(StataCorp, College Station, TX, USA) and SPSS 19.0
(SPSS Inc., Chicago, IL, USA). The characteristics of
patients were reported as proportions for categorical
variables and as median (interquartile range (IQR)) for
continuous variables. Categorical variables were com-
pared with chi-square or Fisher’s exact tests, and con-
tinuous variables were compared with Student’s t test or
the Mann–Whitney U test, as appropriate. The cumula-
tive rates of survival after ECMO initiation were ana-
lyzed using the Kaplan–Meier method, and inter-group
comparisons were performed using the log-rank test. P
values less than 0.05 were considered to be statistically
significant.
The REMEMBER (pRedicting mortality in patients
undergoing veno-arterial Extracorporeal MEMBrane
oxygenation after coronary artEry bypass gRafting) score
was developed according to published recommendations
and using multivariable regression analysis [19, 20].
Briefly, the following steps was used.
Step 1: Identification of “candidate predictors”
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Patients’ demographic, clinical, and biological charac-
teristics prior to ECMO initiation were considered. All
candidate predictors of mortality were assessed with
univariable logistic regression. Continuous variables
were converted into categorical variables for practical
purposes. Variables associated with mortality (p ≤ 0.2)
were included in the multivariable model. The following
known prognostic factors were forced into the final mul-
tivariable model irrespective of their statistical signifi-
cance: pulmonary disease, pre-ECMO cardiac arrest, and
ECMO initiation during cardiopulmonary resuscitation
(CPR). All potential variables included in the multivari-
able analyses were subjected to a correlation matrix for
analysis of multicollinearity.
Step 2: Construction of the REMEMBER score
The multivariate logistic regression model was built
using a backward stepwise selection process in which
variables were removed from the model at each step
based on the p value of more than 0.1. Only variables
with p values ≤ 0.05 were retained in the final multivari-
able model. Regression β coefficients and their 95% con-
fidence intervals (CIs) were re-estimated by logistic
regression with bootstrapping, sampling the whole data
using 1000 repetitions with replacement [21]. To derive
practical REMEMBER component scores, each factor’s β
coefficient retained in the logistic regression model was
divided by the model’s smallest coefficient, multiplied by
5, and rounded to the nearest integer.
Step 3: Internal validation
Logistic regression was used to reassess score perform-
ance in the original dataset. Model discrimination and
calibration were assessed using the area under the receiver
operating characteristics curve (AUROC) and the
Hosmer-Lemeshow C-statistic, respectively. Model discrim-
ination of the REMEMBER score versus the Sepsis-related
Organ Failure Assessment (SOFA) score [22], SAVE score
[14], ENCOURAGE score [15], and EuroSCORE [23] were
compared using AUROC. Moreover, a sensitivity analysis
was performed to determine the performance of the RE-




Five hundred and seventy-seven patients underwent 580
ECMO runs over the 14-year period. Among those patients,
315 patients who did not undergo CABG were excluded.
Finally, 166 patients were retained as the derivation
cohort to create the REMEMBER score (Additional
file 1: Figure S1). Their demographic and pre-ECMO
characteristics are presented in Table 1 and
Additional file 1: Table S3. Briefly, most of the pa-
tients (78%) were diagnosed with unstable angina,
and 52 patients (31%) had left main coronary artery
disease. Eighty-three patients (50%) underwent
off-pump CABG. Sixty patients (36%) were not suc-
cessfully weaned from cardiopulmonary bypass
(CPB) due to PCS requiring transition to ECMO.
Ninety-one patients (55%) suffered from cardiac ar-
rest before VA-ECMO implantation. One hundred
and thirty-two patients (80%) had an IABP placed
before ECMO insertion. Sixty-two percent of all
runs occurred in the late period from 2013 to 2017
(Additional file 1: Figure S2 and Table S3).
Patient outcomes
Ninety-two patients (55%) died in hospital (Additional
file 1: Table S1). Eighty-two deaths (49%) were attributed
to multi-organ failure, 7 (4%) were with anoxic enceph-
alopathy or brain death, and 3 (2%) patients died of car-
diac arrest (Additional file 1: Figure S3). One hundred
and six patients (64%) could be weaned from
VA-ECMO. The median (IQR) time on VA-ECMO sup-
port was 4 (3–6) days. More than 60% of the patients
used ECMO for 3–6 days, and these patients had signifi-
cantly lower mortality than those who used ECMO for
< 3 days (41% vs 81%, p < 0.001) or ≥ 7 days (41% vs 76%,
p = 0.002) (Additional file 1: Figure S4). The median
(IQR) length of ICU stay and hospital stay duration were
8 (5–12) and 20 (13–30) days, respectively. Twenty-five
(15%) patients underwent repeat thoracotomy for bleed-
ing. Major neurological complications were found in 26
(16%) of the patients. Major ECMO-related complica-
tions occurred in 57 (34%) of the patients.
Predictors of in-hospital mortality
Continuous variables were converted into categorical
variables (Additional file 1: Table S4). Variables associ-
ated with mortality at the time of ECMO initiation by
univariable analysis were older age, female, weight ≥ 83
kg, hypertension, diabetes, Canadian Cardiovascular So-
ciety (CCS) class 4 angina, smoking, left main coronary
artery disease, pre-CABG IABP, emergency operation,
inotropic score [24] > 75, diastolic pressure ≤ 45mmHg,
pre-ECMO lactate > 9 mmol/L, hemoglobin < 10 g/dL,
platelet count < 100 × 109/L, serum creatinine > 150
umol/L, and creatine kinase-MB (CK-MB) > 130 IU/L
(Additional file 1: Table S2). Multivariable logistic re-
gression analysis identified older age, left main coronary
artery disease, inotropic score > 75, CK-MB > 130 IU/L,
serum creatinine > 150 umol/L, and platelet count <
100 × 109/L as independent risk factors associated with
in-hospital mortality (Table 2). Bootstrap analysis
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Table 1 Clinical characteristics of the patients at ECMO initiation according to hospital survival status
Characteristic All patients (n = 166) Survivors (n = 74) Non-survivors (n = 92) p value
Age, years 61 (54–67) 57 (50–64) 63 (58–68) < 0.001
Male 132 (80) 64 (86) 68 (74) 0.046
Weight, kg 70 (63–80) 73 (64–80) 70 (63–80) 0.173
Comorbid conditions
Hypertension 99 (60) 38 (51) 61 (66) 0.051
Diabetes 58 (35) 19 (26) 39 (23) 0.025
CCS class 4 angina 55 (33) 20 (27) 35 (38) 0.134
Smoking 92 (55) 47 (64) 45 (49) 0.060
Chronic pulmonary disease 5 (3) 3 (4) 2 (2) 0.481
Left main diseasea 52 (31) 13 (18) 39 (42) 0.001
Diagnosis
Unstable angina 129 (78) 58 (78) 71 (77) 0.853
NSTMI 11 (7) 3 (4) 8 (9) 0.378
STMI 26 (16) 13 (18) 13 (14) 0.545
EuroSCORE 6 (4–7) 5 (3–6) 6 (5–8) < 0.001
Operative parameters
Emergency operation 25 (15) 8 (11) 17 (18) 0.170
OPCABG 83 (50) 38 (51) 45 (49) 0.755
Conversion to on-pump 44 (27) 19 (26) 25 (27) 0.828
LIMA graft 120 (72) 55 (74) 65 (71) 0.599
Number of distal anastomoses 3 (2–4) 3 (2–4) 3 (3–3) 0.648
Unsuccessful weaning off CPB 60 (36) 28 (38) 32 (35) 0.684
Pre-ECMO cardiac arrest 91 (55) 40 (54) 51 (55) 0.859
ECMO initiation during CPR 28 (17) 11 (15) 17 (18) 0.537
Right ventricular failure 11 (7) 4 (5) 7 (8) 0.571
Pre-CABG IABP 32 (13) 10 (14) 22 (24) 0.091
Pre-ECMO IABP 132 (80) 62 (84) 70 (75) 0.222
IABP insertion during ECMO 7 (4) 1 (1) 6 (7) 0.208
SOFA score 12 (10–13) 11 (9–13) 13 (12–14) < 0.001
Inotropic score*b 75 (55–93) 58 (43–83) 82 (67–99) < 0.001
Epinephrinec, μg/kg/min 0.5 (0.35–0.69) 0.40 (0.28–0.65) 0.57 (0.40–0.70) < 0.001
Dobutamined, μg/kg/min 12 (8–16) 10 (8–15) 15 (10–19) < 0.001
Norepinephrinee, μg/kg/min 0.1 (0.06–0.18) 0.1 (0.05–0.15) 0.1 (0.06–0.2) 0.062
Pre-ECMO blood pressureb
SAP, mmHg 70 (58–78) 70 (59–79) 70 (55–77) 0.454
DAP, mmHg 40 (30–50) 40 (32–50) 40 (30–45) 0.163
MAP, mmHg 55 (45–63) 55 (49–65) 55 (45–61) 0.285
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showed the similar results, confirming the stability of
the original model (Additional file 1: Table S5).
REMEMBER score
Six items were retained to create the REMEMBER score
(Table 2). The prediction equation is 1/(1 + exp. (3.856–
0.220*score)). Individual predicted in-hospital CABG-ECMO
mortality risk is calculated by applying the REMEMBER
score to Fig. 1, which displays the 95% CI for mortality of
the development dataset used to derive the score. REMEM-
BER score calibration was good (Hosmer–Lemeshow χ2 p=
0.644; Table 2). Four risk classes, namely class I (REMEM-
BER score 0–13), class II (14–19), class III (20–25), and class
IV (> 25) with their corresponding mortality rates (13%, 55%,
70%, and 94%, respectively), were identified (Fig. 1 and
Additional file 1: Figure S5). When the scoring system was
applied in the four different risk groups, there was very good
overlap between observed and expected mortality in all four
groups (Fig. 1). Cumulative 80-day survival rate by risk class
is shown in Fig. 2. The AUROC for the REMEMBER score
was 0.85 (95% CI 0.79–0.91), which was better than
those of the SOFA, SAVE, EuroSCORE and EN-
COURAGE scores (Fig. 3). The REMEMBER score
exhibited similar performance across both eras (2004–
2012: C = 0.83 (95% CI 0.73–0.93); 2013–2017: C = 0.86
(95% CI 0.79–0.93); Additional file 1: Figure S6). Spear-
man rank correlation matrix for the different scoring
systems is provided in Additional file 1: Table S6.
Table 1 Clinical characteristics of the patients at ECMO initiation according to hospital survival status (Continued)
Characteristic All patients (n = 166) Survivors (n = 74) Non-survivors (n = 92) p value
Biological parametersb
PH 7.35 (7.30–7.39) 7.37 (7.32–7.41) 7.34 (7.28–7.39) 0.058
Serum lactate, mmol/L 11.4 (7.8–17.4) 9.0 (5.5–14.5) 13.8 (9.4–18.4) < 0.001
Hemoglobin, g/dL 9.8 (8.6–10.7) 10.1 (9.2–10.8) 9.2 (8.3–10.6) 0.033
Platelet, ×109/L 103 (58–153) 117 (63–165) 86 (52–132) 0.111
Serum Creatininef, umol/L, 121 (91–160) 96 (80–130) 141 (108–197) < 0.001
CK-MBg, IU/L 143 (48–259) 103 (46–243) 157 (59–281) 0.040
Data are presented as medians (25th–75th percentile) or n (%)
CCS, Canadian Cardiovascular Society classification of angina; NSTMI, non ST-elevation myocardial infarction; STMI, ST-elevation myocardial infarction; CABG,
coronary artery bypass grafting; IABP, intra-aortic balloon pump; OPCABG, off-pump CABG; LIMA, left internal mammary artery; CPB, cardiopulmonary bypass;
ECMO, extracorporeal membrane oxygenation; CPR, cardiopulmonary resuscitation; SOFA score, the Sequential Organ Failure Assessment score; SAP, DAP, and MAP,
systolic, diastolic, and mean arterial blood pressure, respectively; CK-MB, creatine kinase-MB
*Inotropic score, in μg/kg/min, was calculated as follows: dopamine + dobutamine + 100 × epinephrine + 100 × norepinephrine + 15 ×milrinone
aLeft main disease was defined as any stenosis ≥ 50% of the left main trunk
bWorse value within 6 h prior ECMO cannulation
cAll of the patients were treated with epinephrine
dOne hundred and sixty-three patients were treated with dobutamine (73 survivors and 90 non-survivors)
eOne hundred and thirty-nine patients were treated with norepinephrine (62 survivors and 77 non-survivors)
fValues were obtained for 157/166 patients (69 survivors and 88 non-survivors)
gValues were obtained for 160/166 patients (73 survivors and 87 non-survivors)
Table 2 Results of multivariable analyses and the REMEMBER score
Parameter β Coefficient OR (95% CI) p value Score
Age, years
< 54 0 1 0
54–67 1.783 5.95 (2.08–17.06) 0.001 8
> 67 2.384 10.85 (2.71–43.41) 0.001 11
Left main diseasea 1.625 5.08 (2.05–12.57) < 0.001 7
Inotropic score >75b 1.126 3.08 (1.32–7.21) 0.009 5
CK-MB > 130 IU/Lb 1.145 3.14 (1.36–7.24) 0.007 5
Serum creatinine > 150 umol/Lb 1.496 4.46 (1.73–11.53) 0.002 7
Platelet count < 100 × 109/Lb 1.271 3.56 (1.50–8.50) 0.004 6
The prediction equation is:1/(1 + exp. (3.856–0.220*score)). Hosmer–Lemeshow χ2, 6.029 with 8 df; p = 0.644
OR odds ratio, CK-MB creatine kinase-MB
aLeft main disease was defined as any stenosis ≥ 50% of the left main trunk
bWorse value within 6 h prior ECMO cannulation
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Fig. 1 a Predicted mortality at each score level. Curved blue lines represent 95% confidence interval for predicted survival at each score level.
b Hospital mortality by risk class. Observed mortality and predicted mortality are expressed as mean ± 95% confidence interval
Fig. 2 Kaplan–Meier estimates of cumulative probabilities of 80-day survival for patients with the indicated pre-ECMO REMEMBER-score classes
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Discussion
This single-center, retrospective study included 166 PCS
patients supported with VA-ECMO after CABG over a
14-year period and showed that the in-hospital mortality
rate was 55%. We identified risk factors associated with
in-hospital death and developed a mortality risk score
(REMEMBER score), which comprised 6 pre-ECMO
variables, exhibited good performance, and is focused on
patients with PCS following CABG, as compared to
previous scores.
Although ECMO devices and intensive care man-
agement have undergone notable advances over the
past two decades, short-term mortality associated with
PCS remains unacceptably high at 45–75% [1–3, 5–
13, 18, 25–28]. Older age, female sex, obesity, dia-
betes, renal insufficiency, pre-ECMO blood lactate,
elevated CK-MB levels, low serum albumin level, low
platelet count, poor cardiac systolic function, and lo-
gistic EuroSCORE more than 20% were independently
associated with in-hospital death in PCS patients
undergoing ECMO after cardiac-related procedures [1,
2, 7, 9, 11, 27–31]. It had been demonstrated that
older age, female sex, diabetes, left main disease, and
elevation of CK-MB levels were independent risk fac-
tors for death of CABG patients [32–36]. However,
there is a paucity of data on patients receiving
VA-ECMO after isolated CABG. In a recent retro-
spective study [7] involving 148 patients with PCS
after CABG, in-hospital mortality was 64.2%, which
was higher than that of our series. Moreover, the au-
thors found that creatinine clearance, pulmonary
disease, and pre-VA-ECMO blood lactate were inde-
pendently associated with in-hospital death.
Despite these previously reported mortality risk fac-
tors, there are no published scoring system based on
pre-ECMO parameters to predict the outcomes of
VA-ECMO-supported CABG patients with PCS re-
fractory to conventional treatment. The REMEMBER
score incorporates six simple pre-ECMO variables
and demonstrated good performance (AUROC 0.85)
in the derivation cohort. All these parameters are
readily measurable and available to clinicians before
VA-ECMO implantation. Our study highlights the im-
portance of older age in determining in-hospital
death, which was reflected in its weighting in the RE-
MEMBER score. The other five variables had similar
weightings in the score. Our findings also confirmed
that the presence of left main disease, elevated
CK-MB, acute kidney injury, and thrombocytopenia at
ECMO initiation were associated with poorer out-
comes. In addition, inotropic score was related to
short-term death, which was used to roughly estimate
the severity of the pre-ECMO status [24].
Scoring systems are often used to select appropriate
patients for specific therapies [37, 38]. However, for PCS
patients who clinicians believe would die without
VA-ECMO, decision-making by clinicians often involves
many patient and contextual factors and remains diffi-
cult despite the use of prediction models. Risk stratifica-
tion, however, will inform family members and clinicians
of the likely risk of death for a group of patients with a
similar risk profile undergoing the proposed operation.
Fig. 3 The areas under the receiver operating characteristic curves for predicting in-hospital death. Discriminatory performance of REMEMBER
score was greater than other scores
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The present study identified four risk classes according
to the REMEMBER score. The score might aid in family
counseling and shared decision-making relative to clin-
ical outcomes and help clinicians identify high-risk
post-CABG patients who may suffer poor outcomes des-
pite the use of the VA-ECMO.
In the past few years, the SAVE [14] and ENCOUR-
AGE [15] scores have been developed to predict survival
of patients receiving ECMO for refractory cardiogenic
shock. The EuroSCORE [23] and SOFA [22] scores are
widely used in the fields of cardiac surgery and critical
care, respectively. Importantly, the REMEMBER score
had better discrimination than these previously pub-
lished scores in our cohort. In our scoring system,
female patients were not at increased risk of death,
which differed from that in the EuroSCORE [23] and
ENCOURAGE [15] score. While female sex was signifi-
cantly associated with mortality in univariable analyses,
it was not retained in the final multivariable logistic
regression model (p = 0.065). One possible explanation
was the relatively small number of women in our study.
Pre-ECMO cardiac arrest was found to be associated
with the increased mortality in the SAVE score [14],
whereas this phenomenon was not observed in our
study. Most of these patients suffered from in-hospital
cardiac arrest and had very short no- and low-flow
times, which might account for our findings. Another
difference between our score and the ENCOURAGE
[15] score was our lack of an association between the
serum lactate and in-hospital death, potentially owing to
some patients surviving to hospital discharge despite
initially high lactate levels.
Our study has several limitations. First, it was a
single-center, retrospective study which may limit the
generalizability of our results. Second, because left
ventricular assist devices were not registered in China,
no patients underwent ventricular assist device after
VA-ECMO. The usefulness of VA-ECMO for CABG
patients might have therefore been underestimated.
Third, since patients requiring VA-ECMO before iso-
lated CABG were not included in our study, the ap-
plicability of the REMEMBER score to these patients
remains unknown. Fourth, half of the patients under-
went off-pump CABG. On-pump CABG is the pre-
ferred surgical procedure for coronary artery disease
patients in many other centers with extensive surgical
experience [39, 40]. However, off-pump CABG was
not associated with outcomes in the present study.
Fifth, our institution tries to do VA-ECMO early
which may represent different strategy/threshold than
other centers. Finally, we performed only an internal
validation of the REMEMBER score. Prospective
studies are needed to externally validate the scoring
system before it can be widely applied.
Conclusions
In our cohort of patients undergoing isolated CABG
complicated by PCS requiring VA-ECMO, older age,
left main disease, inotropic score > 75, CK-MB > 130
IU/L, serum creatinine > 150 umol/L, and platelet
count < 100 × 109/L were identified as pre-ECMO
prognosis factors of in-hospital mortality. The RE-
MEMBER score might help clinicians at bedside to
predict in-hospital mortality for patients receiving
VA-ECMO after CABG for refractory cardiogenic
shock.
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